Norovirus vaccine against experimental human Norwalk Virus illness.

ABSTRACT:

Background

Noroviruses cause epidemic and sporadic acute gastroenteritis. No vaccine is available to prevent norovirus illness or infection.

Methods

We conducted a randomized, double-blind, placebo-controlled, multicenter trial to assess the safety, immunogenicity, and efficacy of an investigational, intranasally delivered norovirus viruslike particle (VLP) vaccine (with chitosan and monophosphoryl lipid A as adjuvants) to prevent acute viral gastroenteritis after challenge with a homologous viral strain, Norwalk virus (genotype GI.1). Healthy adults 18 to 50 years of age received two doses of either vaccine or placebo and were subsequently inoculated with Norwalk virus and monitored for infection and gastroenteritis symptoms.

Results

Ninety-eight persons were enrolle

SUBMITTER: Atmar RL 

PROVIDER: S-EPMC3761795 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature